Miniaturisation is the clinical process through which androgenetic hair loss occurs, and understanding it clarifies why the condition progresses the way it does and why early treatment is more effective than late intervention.
Under the influence of DHT (dihydrotestosterone), genetically susceptible hair follicles undergo a progressive shrinking process. Each successive hair growth cycle produces a hair that is slightly thinner, shorter, and lighter in colour than the one before. Over years, what was once a healthy terminal hair producing a thick, pigmented shaft becomes a miniaturised follicle producing a barely visible vellus hair — the fine, colourless down seen on a balding scalp.
The follicle is not dead at this stage — it is merely miniaturised. This is an important distinction because it means that medical treatments such as finasteride, which reduce DHT levels, can reverse miniaturisation in follicles that have not yet fully dormant. Follicles that have been miniaturised for a short time respond better to treatment than those that have been in that state for years.
Trichoscopy — magnified examination of the scalp — can identify miniaturisation at an early stage, before it is visible to the naked eye. Seeing a high proportion of miniaturised follicles in a given area tells a surgeon that those follicles are unlikely to survive long term without medical support, and that the coverage from native hair in that area should not be relied upon when planning a transplant.
Starting treatment early, before significant visible loss has occurred, is the most effective approach to managing androgenetic alopecia. The goal of medical therapy is to slow or halt the miniaturisation process — and the earlier it begins, the more follicles remain to be preserved.
Related reading
